The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 12, 2011, Pages 1192-1199

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Yan, Bing Zhu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

chronic hepatitis C; infection; neutropenia; risk factor

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL INFECTION; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL INFECTION; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; URINARY TRACT INFECTION;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-ALPHA; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS;

EID: 80955145772     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834c5b32     Document Type: Article

References (25)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, et al. Suppression of haematopoiesis during therapy chronic hepatitis C with different interferon alfa mono and combination therapy regimens. Gut 2005; 54:1014-1020. (Pubitemid 40873919)
3. Dieterich DT, Spivak JL. Hematologic disorder associated with hepatitis C virus infection and their management. Clin Infect Dis 2002; 37:533-541.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg-interferon alfa-2b plus ribavirin plus interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
5. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 2000; 49:1-128.
6. Tien PC. Management of treatment of hepatitis C virus infection in HIV-infected adult: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol 2005; 100:2338-2354.
7. Viscoli CEORTC International Antimicrobial Therapy Group. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002; 38:S82-S87.
8. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132:103-112. (Pubitemid 46127673)
9. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010; 52:1225-1231.
10. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273-1279. (Pubitemid 35253446)
11. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42:1674-1678. (Pubitemid 43839429)
12. Yang JF, Hsieh MY, Hou NJ, Dai CY, Huang JF, Lin ZY, et al. Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment Pharmacol Ther 2009; 29:1000-1010.
13. Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008; 36:250-255.
14. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124-129. (Pubitemid 46096836)
15. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148. (Pubitemid 34032554)
16. Quesada JR, Talpaz M, Rios A. Clinical toxicity of interferon in cancer patients: a review. J Clin Oncol 1986; 4:234-243. (Pubitemid 16161041)
17. Puoti M, Babudieri S, Rezza G, Viale P, Antonini MG, Maida I, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004; 9:627-630. (Pubitemid 39150220)
18. Juarez-Navarro A, Vera-de-León L, Navarro JM, Chirino-Sprung R, D́iaz-Hernandez M, Casillas-Davila L, et al. Infection and severity of infection according to the development of neutropenia during combined therapy with pegylated interferon-alfa-2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Phamarcol 2005; 27:317-322. (Pubitemid 41044273)
19. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-728.
20. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taura P, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34:32-37.
21. Navarini AA, Recher M, Lang KS, Georgiev P, Meury S, Bergthaler A, et al. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA 2006; 103:15535-15539. (Pubitemid 44625627)
22. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:1041-1050.
23. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29-34. (Pubitemid 27019919)
24. Ioannou S, Hatzis G, Vlahadami I, Voulgarelis M. Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report. J Med Case Reports 2010; 4:268.
25. Chang CS, Yan SL, Lin HY, Yu FL, Tsai CY. Pure red cell aplasia caused by pegylated interferon-a-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol 2011; 17:2155-2158.